Current status of the development of trans-platinum antitumor drugs

✍ Scribed by José M Pérez; Miguel A Fuertes; Carlos Alonso; Carmen Navarro-Ranninger

• Publisher: Elsevier Science
• Year: 2000
• Tongue: English
• Weight: 163 KB
• Volume: 35
• Category: Article
• ISSN: 1040-8428
• DOI: 10.1016/s1040-8428(00)00053-6

✦ Synopsis

The discovery in the 1990s of several trans-Pt complexes with in vitro and in vivo activity against tumor cells sensitive and/or resistant to cisplatin has forced the re-evaluation of the structure-activity relationships for platinum antitumor drugs. Because the determinant factors of cytotoxic activity of trans-platinum complexes do not follow the same patterns as those found for cisplatin and its analogues, the differences in cellular and biochemical pharmacology between trans-platinum antitumor complexes and cisplatin might be systematically exploited to design novel trans-platinum complexes with a clinical profile complementary to that of cisplatin and related analogues. Therefore, there may exist a novel molecular rationale for new platinum antitumor drugs development in the twenty-first century.